[CAS NO. 107753-78-6] Zafirlukast (ICI-204219)

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [107753-78-6]

Catalog

SLK-S1633

Brand

Selleck

CAS

107753-78-6

DESCRIPTION [107753-78-6]

Overview

MDL	MFCD00864775
Molecular Weight	575.68
Molecular Formula	C31H33N3O6S
SMILES	C(C=1C=2C(N(C)C1)=CC=C(NC(OC3CCCC3)=O)C2)C4=C(OC)C=C(C(NS(=O)(=O)C5=C(C)C=CC=C5)=O)C=C4

For research use only.

Storage

3 years,-20°C,powder
1 years,-80°C,in solvent

Shipping

Room temperature shipping(Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Concentration Volume Mass	1 mg	5 mg	10 mg
1 mM	1.7371 mL	8.6854 mL	17.3708 mL
5 mM	0.3474 mL	1.7371 mL	3.4742 mL
10 mM	0.1737 mL	0.8685 mL	1.7371 mL
50 mM	0.0347 mL	0.1737 mL	0.3474 mL

Description

Zafirlukast (ICI-204219) is an oral antagonist (LTRA), used to prevent asthma symptoms.

Targets

leukotriene receptor ^[1]

In vitro

Zafirlukast is similar to 3-methylindole because it contains an N-methylindole moiety that has a 3-alkyl substituent on the indole ring. Zafirlukast readily forms (10% conversion in 60 min) a GSH adduct with molecular mass of 880 Da upon incubation with horseradish peroxidase. Zafirlukast produces time-, concentration-, and NADP(H)-dependent inactivation of CYP3A4. Zafirlukast is shown to inhibit CYP3A enzyme activity in vitro (nonpreincubation inhibition) with a Ki of 2 μM in one report, but higher values have been published, and our KI for the inactivation process is 13.4 μM. Zafirlukast has high plasma protein binding (>99%), which would lower the free-drug concentration. Zafirlukast undergoes two successive one-electron oxidations to afford a highly electrophilic α,β-unsaturated iminium species, which reacts spontaneously with GSH to yield the observed adduct.

In vivo

Zafirlukast is a potent and selective cysteinyl leukotriene receptor antagonist which is used mainly in the prophylaxis of bronchial asthma. Zafirlukast in a dose of 80 mg/kg orally produces a significant decrease in tissue malondialdehyde, myeloperoxidase, and an increase in both reduced glutathione and catalase levels, while there is no significant changes with the rectal route.

References

[1] Kassahun K, et al. Chem Res Toxicol,?005, 18(9), 1427-1437.
[2] Mahgoub AA, et al. Toxicol Lett,?003, 145(1), 79-87.

Synonyms

Carbamic acid, N-[3-[[2-methoxy-4-[[[(2-methylphenyl)sulfonyl]amino]carbonyl]phenyl]methyl]-1-methyl-1H-indol-5-yl]-, cyclopentyl ester

Carbamic acid, [3-[[2-methoxy-4-[[[(2-methylphenyl)sulfonyl]amino]carbonyl]phenyl]methyl]-1-methyl-1H-indol-5-yl]-, cyclopentyl ester

ICI 204219

Cyclopentyl 3-[2-methoxy-4-[(o-tolylsulfonyl)carbamoyl]benzyl]-1-methylindole-5-carbamate

Zafirlukast

Accolate

Vanticon

S 1633

[3-[2-Methoxy-4-(toluene-2-sulfonylaminocarbonyl)-benzyl]-1-methyl-1H-indol-5-yl]-carbamic acid cyclopentyl ester